Sign Up for a Free Account
  • Updated 05.25.2020
  • Released 05.25.2020
  • Expires For CME 05.25.2023

Onasemnogene abeparvovec

Introduction

This article includes discussion of onasemnogene abeparvovec, AVXS-101, onasemnogene, onasemnogene abeparvovec, onasemnogene abeparvovec-xioi, and Zolgensma. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.

Historical note and terminology

Onasemnogene abeparvovec is a gene therapy for delivery of a functional copy of the human survival motor neuron (SMN) gene to the motor neuron cells of patients with spinal muscular atrophy type 1 and is the first gene therapy to be approved for the treatment of spinal muscular atrophy in the United States in May 2019 (05). It was approved by the European Commission in May 2020. It will compete with intrathecal nusinersen, a splice-modulating antisense oligonucleotide, approved for the treatment of spinal muscular atrophy type 1 in 2016.

Start a MedLink Neurology trial
to unlock 3 free articles.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com